Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
APGA Annual ConferenceAPGA Annual Conference
Not Confirmed
Not Confirmed
20-23 July, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
APGA Annual ConferenceAPGA Annual Conference
Industry Trade Show
Not Confirmed
20-23 July, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
10 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/cristcot-appoints-richard-kim-as-chief-commercial-officer-302476944.html
30 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/30/3071287/23024/en/Intercept-Announces-Data-to-be-Presented-at-Digestive-Disease-Week-2025.html
17 Apr 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/ipsens-liver-disease-drug-iqirvo-promising-launch-battle-gileads-livdelzi
12 Dec 2024
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/vraylar-sales-growth-seen-slowing-2025-says-richter-ceo-2024-12-12/
13 Nov 2024
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-full-approval-intercepts-liver-disease-drug-2024-11-12/
12 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/12/2979130/23024/en/Intercept-Receives-Complete-Response-Letter-from-FDA-Addressing-OCALIVA-supplemental-New-Drug-Application-sNDA.html
ABOUT THIS PAGE